source
- Pharvaris reports 83% drop in hereditary angioedema attacks in phase 3 trial, FDA decision pendingPharvaris announced that its oral bradykinin B2 receptor antagonist, deucrictibant, met the primary goal in a second phase 3 study. The trial, called CHAPTER-3, enrolled 85 patients with three for…
- Novartis shares tumble after late-stage failure of Avidity-acquired drugNovartis announced that its late-stage trial of a drug it acquired from Avidity did not meet its primary endpoints. The setback follows a recent disappointment in a heart disease study, adding pres…